HMG-CoA reductase inhibitors (statins): A promising approach to stroke prevention

David C Hess, Andrew M. Demchuk, Lawrence M. Brass, Frank M. Yatsu

Research output: Contribution to journalReview articlepeer-review

110 Scopus citations


Statins represent a promising class of agents to prevent stroke. In randomized trials of middle-aged patients with coronary artery disease, statins reduce the incidence of stroke. The reduction in stroke may not be solely related to cholesterol or low-density lipoprotein reduction but may involve nonsterol mechanisms effects on endothelia cells, macrophages, platelets, and smooth muscle cells. Statins also reduce the size of cerebral infarction in a murine stroke model, suggesting a neuroprotective effect. The best current evidence for stroke prevention is with pravastatin and simvastatin. Pravastatin reduces the risk of stroke in patients with coronary artery disease and average cholesterol levels simvastatin reduces the risk of the combined endpoint of stroke and transient ischemic attack in hypercholesterolemic patients with coronary artery disease. Future studies of statins are needed in stroke populations, particularly the elderly.

Original languageEnglish (US)
Pages (from-to)790-796
Number of pages7
Issue number4
StatePublished - Feb 22 2000


  • Cholesterol
  • CoA reductase inhibitors
  • HMG
  • Prevention
  • Statins
  • Stroke

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'HMG-CoA reductase inhibitors (statins): A promising approach to stroke prevention'. Together they form a unique fingerprint.

Cite this